OBIO

Orchestra BioMed Holdings, Inc. (OBIO) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Orchestra BioMed is a biomedical innovation company focused on developing high-impact technologies through risk-reward sharing partnerships. Its flagship product candidates are AVIM Therapy for hypertension (in collaboration with Medtronic) and Virtue SAB for atherosclerotic artery disease. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: Revenue consists of partnership revenue (Terumo) and product revenue (FreeHold). The company has an accumulated deficit of $368.8 million as of September 30, 2025.

Material Changes vs. Prior Period

• Revenue: Total revenue increased 8% year-over-year for the nine months ended September 30, 2025, driven by a 10% increase in partnership revenue. However, Q3 2025 revenue declined 13% compared to Q3 2024.
• Expenses: Research and Development (R&D) expenses increased 30% year-over-year (YTD) to $41.4 million, primarily due to increased clinical development costs for the BACKBEAT study and the initiation of the Virtue Trial. Selling, General, and Administrative (SG&A) expenses increased 9% YTD.
• Financing Activity: In August 2025, the company completed a public offering and private placements raising approximately $62.6 million in gross proceeds. Additionally, the company entered into a Royalty Purchase Agreement with Ligand Pharmaceuticals, receiving $20.0 million in the first tranche.
• Debt Structure: The company amended its 2024 Loan and Security Agreement with Hercules Capital to delay amortization payments and increase the discretionary borrowing limit. A new $20.0 million convertible loan agreement with Medtronic was signed, with funding expected in April 2026.

Guidance, Outlook, and Risks

• Clinical Progress: The company announced the initiation of the Virtue Trial (U.S. IDE pivotal study for Virtue SAB) in October 2025, with enrollment planned for mid-2027. The BACKBEAT study for AVIM Therapy is ongoing, with enrollment completion estimated for mid-2026.
• Terumo Agreement Termination: On October 24, 2025, the company terminated its distribution agreement with Terumo. In exchange, the company received a $10.0 million fee and granted Terumo a Right of First Refusal (ROFR) for Virtue SAB in coronary artery disease. The company retained rights to other vascular indications.
• Liquidity Outlook: Management believes current cash, marketable securities, and committed future funding (including $20M from Medtronic and $15M from Ligand) are sufficient to fund operations into the fourth quarter of 2027.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital, and the high effective interest rate (approx. 22.5%) associated with the Royalty Purchase Agreement. The company also faces potential dilution from the resale of shares registered under a Resale Registration Statement.

Investor Verification Checklist

• Terumo ROFR Terms: Verify the specific conditions under which Terumo can exercise its Right of First Refusal and the timeline for the ROFR period relative to the Virtue Trial data disclosure.
• Royalty Purchase Agreement Economics: Review the tiered royalty percentages (17% to 20% initially) and the impact of the 22.5% effective interest rate on future profitability.
• Medtronic Loan Funding: Confirm the closing conditions for the $20.0 million Medtronic Loan scheduled for April 2026 and the conversion mechanics into revenue share.
• Cash Burn Rate: Monitor the quarterly cash burn rate against the projected runway to Q4 2027, considering the increased R&D spend for the Virtue Trial.
• Stock Dilution: Assess the potential market impact of the 18.6 million shares registered for resale and the conversion of Series A Preferred Stock issued to Terumo.